Rev. Colomb. Cienc. Quím. Farm., Vol. 48(2), 411-424, 2019
www.farmacia.unal.edu.co
Scientific research article / http://dx.doi.org/10.15446/rcciquifa.v48n2.82718
Effect of Lippia alba essential oil
administration on obesity and
T2DM markers in Wistar rats
Maria Victoria Acevedo-Estupiñana, Elena Stashenkob, Fernando Rodríguez-Sanabriac
a
Universidad Industrial de Santander, Medicine School, Basic Sciences Department, Research
Group on Tropical Diseases (CINTROP). Programa Joven Investigador (Young Researcher
program), Colciencias, 2013, Cra. 32 # 29-31, Bucaramanga, Santander, Colombia.
b
Universidad Industrial de Santander, Basic Science School, Chemistry Department, Research
Center for Agro-industrialization of Tropical Medicinal Aromatic Plant Species (CENIVAM),
Cra. 27 calle 9, Bucaramanga, Santander, Colombia.
c
Universidad Industrial de Santander, Medicine School, Basic Sciences Research Department,
Group on Tropical Diseases (CINTROP) and Research Group of Human Genetics, Cra. 32 #
29-31, Bucaramanga, Santander, Colombia.
*E-mail: frodrig@uis.edu.co
Received: February 12, 2019
Accepted: July 2, 2019
Summary
Introduction: Lippia alba (Mill) N.E. Brown (Verbenaceae) is an aromatic plant
from Central America, South America, and the Caribbean, it is traditionally used by
the Colombian population to treat various diseases such as diabetes and hypertension. The purpose of this research was to evaluate the metabolic effects of Lippia alba
essential oil (EO) oral administration on obesity and diabetes markers in Wistar
rats. Methods: control and Streptozotocin (STZ) diabetes induced rats were used
to evaluate the EO metabolic effects. Glucose and triglycerides were measured using
commercial colorimetric kits, the animals’ weight was followed for 21 days treatment and TNF- and adiponectin concentration was determined with ELISA technique. Results: The consumption of EO shows body weight gain regulation, lower
glucose and cholesterol levels in normal rats and lower TNF- in comparison with
the Glibenclamide treated rats between the STZ diabetic groups. No toxic effects
were founded. Conclusions: The EO exerts a benefical metabolic effect in rats,
therefore it is interesting to be evaluate a future in human beings with T2DM or
overweight.
Key words: Cytokines, essential oil, Lippia alba, metabolism, obesity, type 2 diabetes mellitus.
411
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
Resumen
Efecto de la administración del aceite esencial de Lippia alba sobre
la obesidad y los marcadores T2DM en ratas wistar
Introducción: Lippia alba (Mill) N.E. Brown (Verbenaceae) más conocida como
pronto alivio, es una planta aromática de Centro, Sur América y el Caribe que se
utiliza tradicionalmente en Colombia para el tratamiento de diversas enfermedades,
como la diabetes e hipertensión. El objetivo del trabajo fue evaluar el efecto metabólico del aceite esencial de Lippia alba (Mill), administrado oralmente, sobre moléculas relacionadas con obesidad y diabetes en ratas Wistar. Métodos: se pesaron los
animales diariamente. Después de 21 días de tratamiento con el AE se determinó en
plasma la glucosa, triglicéridos con kits comerciales y las adipocitoquinas (adiponectina y factor de necrosis tumoral alfa (TNF) marcadores de resistencia a la acción
de la insulina) por la técnica de ELISA. Resultados: el consumo de AE mostró una
regulación en la ganancia de peso corporal y disminución en los niveles de glucosa
y triglicéridos en los animales normales que recibieron el AE. Dentro de los grupos
con diabetes inducida, el grupo tratado con AE mostró menores valores de TNF-
comparado con el grupo tratado con glibenclamida. Conclusiones: el AE ejerce un
efecto benéfico en el metabolismo de los animales, por lo tanto, es interesante para
ser evaluado en seres humanos con diabetes o sobrepeso.
Palabras clave: Metabolismo, aceite esencial, Lippia alba, adipocitoquinas, obesidad,
DMT2.
Introduction
Throughout its existence, humans have faced hunger and diseases periods that have
threatened with its extinction. Their survival has depended on the ability to store
energy and use it in times of limited food availability as well as the ability to cope with
infections and the damages caused by them.
This is how the metabolic and immune systems have ensured the basic requirements
for survival and have evolved together, although independently. Several hormones,
cytokines, transcription factors, and lipids participate in both systems and, in addition
to using the same metabolic and immune mechanisms, they can regulate each other
[1]. For instance, a normal inflammatory response needs active metabolic pathways to
divert energy, which is the case of stored lipids that are mobilized in the fight against an
infection during the acute phase response. The inflammatory response (obesity is considered a state of chronic inflammation) favors a catabolic state and suppresses anabolic
pathways, such as the insulin signaling pathway [2].
412
Effect of Lippia alba EO administration in Wistar rats
Nowadays, excessive consumption of energy-rich foods has now become a serious public
health problem in the world, which, along with wrong lifestyles, has led to the emergence
of two diseases which are characteristic of the Western Hemisphere: obesity and type 2
diabetes. The biochemical consequences in an overweight organism are energy imbalance and metabolic stress that produce an inflammatory and oxidizing response [3].
Initially, the treatment of these two diseases is aimed at decreasing weight and glucose
in the plasma by means of diet and aerobic exercise. However, lack of commitment to
this treatment causes hypoglycemic agents and medications to be prescribed in order
to help body weight regulation.
Hypoglycemic agents on the market, although effective in controlling plasma glucose,
have undesirable and sometimes serious side effects for the individuals who take them;
In addition, the medications used to maintain body weight are not safe enough for
human health. Therefore, it is necessary to search for new pharmacological alternatives with fewer side effects that allow combatting the symptoms of these two diseases:
inflammation and hyperglycemia by regulating the molecules involved [1].
Lippia alba Mill N.E. Brown (Family Verbenaceae) is an aromatic plant of the Center,
South America, and the Caribbean. Traditionally, it has been used for the treatment
of various diseases such as diabetes, hypertension, respiratory and digestive conditions
[4-6]. From this plant, different essential oils are extracted. In the present study, L. alba
chemotype carvone was used, which has been tested due to its antifungal, antibacterial, anxiolytic and antioxidant activity [7-10]. The latter property is very interesting,
as several studies suggest that oxidative stress plays a central role in the pathogenesis of
various metabolic diseases such as diabetes and obesity [11, 12].
The objective of this study was to evaluate the metabolic effect of Lippia alba Mill N.E.
Brown chemotype carvone EO on molecules related to type 2 diabetes mellitus (T2DM)
and obesity as TNF alfa and adiponectin cytokines using Wistar rats as test subjects.
Methodology
Animals
This study used Wistar rats ranging from 200 to 250 g, which came from Universidad
Industrial de Santander’s Health Faculty’s Bioterium; The rats were kept in optimum
housing conditions, light and dark cycles of 12 hours, water and food ad libitum, temperature 22 ± 2°C and humidity 50-60%. In all procedures, the ethical considerations
of Directive 2010/63 of the European Union were taken into account [13]. The Ethics
Committee of Universidad Industrial de Santander - ECINCI approved this work.
413
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
Toxicity analysis
To test the acute oral toxicity of the oil, the methodology proposed by the OECD was
followed [14]. Twenty-four Wistar rats (12 females and 12 males) were divided into
four groups of females and four groups of males. They were given 0, 10, 200 and 500 μL
/ kg body weight of L. alba EO using 0.5% Carboxymethylcellulose (CMC) as carrier.
Behavior changes and disease symptoms such as excitement, fatigue, lethargy, itching,
hair loss, diarrhea, backache, tremor and death for 1 hour after 6, 12 and 24 hours and
every day for 14 days were observed.
Blood samples collected after 14 observation days were used to determine, by commercial colorimetric kits, AST and ALT transaminases, markers of liver damage.
Induction of diabetes using streptozotocin
The induction of diabetes was performed in three groups of Wistar rats of five animals
each, fasted for eight hours. Subsequently, a single intraperitoneal injection of streptozotocin (STZ) (Sigma, USA) of 50 mg/kg in fresh 0.1 M citrate buffer (pH 4.5) was
applied [15]. In addition, a 20% glucose solution was given during the following 24
hours which allowed them to cope with the initial hypoglycemic effects of STZ [16].
Essential oil of Lippia alba Mill N.E. Brown
The essential oil (EO) was obtained by microwave-assisted hydro-distillation
(MWHD) of L. alba (Carvone chemotype), grown at the Research Center for Agroindustrialization of Tropical Medicinal Aromatic Vegetable Species (CENIVAM),
Bucaramanga, Colombia, with a yield of 0.6% (w/w). The identification of the plant
and its deposit are in the National Herbarium with voucher N°. 512078. EO characterization (see table 1) was performed by gas chromatography coupled to mass spectrometry with the methodology published [8,9,17] at Universidad Industrial de Santander’s
-UIS Center of Chromatography and Mass Spectrometry -CromMass.
Table 1. Principal components of L. alba EO (carvone chemotype).
414
Compound
% in oil
Carvone
38.3
Limonene
35.8
Bicyclesesqui phellandrene
12
Piperitone
5.1
Piperitenone
4.4
β-Bourbonene trans-β-caryophyllene
1.3
Effect of Lippia alba EO administration in Wistar rats
Experimental design with working groups
Male Wistar rats were divided into five groups (see table 2), each with five animals. The
0.5% CMC compound was used as carrier. The highest non-toxic dose of EC was chosen. Diabetes in rats was induced with STZ as specified in the methodology. All doses
were given daily for 21 days and were administrated orally by gastric tube.
Table 2. Working groups’ experimental design.
Group
Induction Vehicle
of diabetes CMC %
Treatment
Essential oil
Glibenclamide
Control (C)
No
0.5
----
----
Diabetic control (DC)
Yes
0.5
----
----
Yes
0.5
----
10 mg/kg bw*
Yes
0.5
500 µL EO/kg bw
----
No
0.5
500 µL EO/kg bw
----
Diabetic treated with
Glibenclamide (G)
Diabetic treated with essential
oil (EOD)
Control treated with essential
oil (EOC)
*bw: Body weight
During the 21 days of treatment, the body weight of each animal was recorded. After
day 21, the animals were fasted for 12 hours and sacrificed by decapitation; their blood
was collected, and the serum was separated by centrifugation to perform the determinations using commercial cholesterol, triglyceride, AST, ALT and ALP colorimetric kits.
Essential oil effect on the intestinal glucose absorption glucose and concentration of
triglycerides and serum glucose concentration
First, the absorption and metabolism of plasma glucose against an oral glucose load
were evaluated using an AccuTrend plus kit and glucose test strips from Roche Laboratories. To perform the glucose curve, before starting EO treatment, the first blood
sample (basal value) was taken on fast without supplying the glucose load to the animal, the second sample was taken thirty minutes after having given the glucose load,
and the third and fourth samples 60 and 120 min, respectively, after having given the
glucose load to the animals. The glucose load applied was 2 g of glucose per kg of animal weight.
415
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
Second, evaluation of serum glucose and triglyceride concentrations of fasting animals
after 21 days of treatment was performed using commercial colorimetric kits.
Evaluation of adipocytokines
The serum concentration of adiponectin and TNF-α of the animals under study after
21 days of oral treatment with the essential oil was determined by the ELISA technique
following the protocol suggested in kits ab108784 and ab46070 abcam Laboratories.
Statistical analysis
A one-way analysis of variance (ANOVA) was performed using the Tukey HSD test
for normalized data and the non-parametric Kruskal-Wallis test, followed by Tukey
HSD for non-normalized data ref. A value of p <0.05 was considered statistically significant. Statistical packages SIGMASTAT and STATISTICA 8.0® were used.
Results
Toxicity analysis
Toxicity studies revealed that in the control group the doses evaluated (10, 200 and
500 mg/kg) were safe. Animals of either sex showed no signs of toxicity or change
in their behavior, which was corroborated by liver function evaluation. The AST and
ALT hepatotoxicity markers did not show any variations with regarding the control
group at the doses evaluated for the L. alba EO.
Glucose absorption and metabolism, and diabetes induction with STZ
The oral glucose tolerance test performed on all work groups prior to initiating EO
treatment did not show alterations in glucose uptake, figure 1, including the groups
that were induced diabetes with STZ. At minute 30, all groups evaluated were able to
absorb glucose (serum increases in glucose concentration) and were also able to regulate it at minutes 60 and 120 (serum decreases in glucose concentration). This decrease
is caused by the presence of insulin. Therefore, it is evident that even the groups of animals that were induced by diabetes with STZ showed insulin remnants which resembles type 2 diabetes mellitus. This indicates that despite being treated with STZ, this
drug’s concentration is important in determining the model of diabetes to be developed [18-20].
416
Effect of Lippia alba EO administration in Wistar rats
Glucose, mg/dL
400
300
200
100
0
60
120
Time, min
C
DC
EOC
G
EOD
Figure 1. Oral glucose tolerance test before initiating EO treatment for all groups evaluated: (C)
control, (DC) Diabetic, (G) Diabetic Glibenclamide 10 mg/kg, (EOD) diabetic EO and (EOC)
EO control).
Metabolic effects caused by the ingestion of EO from Lippia alba
Effect on body weight.
The weight gained by the animals in the different groups showed significant differences
since the animals submitted to the EO treatment gained less weight than the animals
in the groups that did not receive it (Figure 2).
60
*o
weight gain [%]
*
*o
40
20
C
G
DC
EOD
C
EO
D
EO
G
C
D
C
0
EOC
Figure 2. Percentage of increase in the body weight of the evaluated animals at the end of the 21 days
of experimentation in each of the groups: (C) control, (DC) Diabetic, (G) Diabetic Glibenclamide
10 mg/kg, (EOC) EO control, P <0.05 with respect to EOC (*) and with respect to EOD (°).
417
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
Cumulative hepatotoxicity analysis
In Figure 3, the results of analyses performed to determinate the levels of AST liver
enzymes and ALT are presented.
Transaminases [U/L]
300
200
100
*
AS
AL
T
T
0
C
G
DC
EOD
EOC
Figure 3. Activity of liver enzymes AST and ALT in serum after 21 days of treatment with EO.
Groups: (C) control, (DC) Diabetic, (G) Diabetic Glibenclamide 10 mg / kg, (EOD) diabetic EO
and (EOC) control EO. Data are presented as means ± SEM. P <0.05 with respect to EOC (*).
The evaluated aminotransferases do not show that EO has long term toxic consequences, only significant differences were found between groups C and EOC of the
ALT enzyme. However, their difference does not reach between 3-15 times the value
of the normal control, which could indicate the presence of hepatic injury. There are
other factors that may alter this enzyme such as body mass index, food intake, exercise,
among others [21]. These factors are congruent with the results found in this study
with respect to body weight.
Serum glucose and triglyceride concentration.
In Figure 4, a significant decrease was observed in the EOC group of glucose and triglycerides regarding group C. The decrease in glucose and triglycerides corresponds
to 33 and 35%, respectively; Values that are lower than those presented by the group
of animals treated with Glibenclamida® (group G). It is noteworthy that the animals
that were induced by diabetes and that were treated with the EO, EOD group, did not
show significant changes with by comparison to the control diabetic group, DC, in
terms of triglycerides and glucose.
418
Effect of Lippia alba EO administration in Wistar rats
200
*
*
*
100
Triglycerides [mg/dL]
*
50
0
*
*
150
100
50
C
G
DC
EOD
EOC
C
D
G
C
G
DC
EOD
EO
D
EO
C
EO
C
D
G
D
EO
C
C
0
C
Glucose [mg/dL]
150
EOC
Figure 4. Effect of administration of L. alba EO at the end of 21 days of treatment in biochemical
analyzes: (A) Glucose and (B) Triglycerides. Groups: (C) control, (DC) Diabetic, (DG) Diabetic
Glibenclamide 10 mg/kg, (EOD) diabetic AE and (EOC) AE control. All results presented are
expressed in [mg/dL]. * P <0.05 with respect to the EOC group.
Effect on adipocytokines.
The essential oil’s effect on evaluated adipocytokines, adiponectin and TNF-, shows
that adiponectin from the groups of animals that consumed EO (EOD and EOC) did
not differ significantly from the control group (C), Figure 5A.
14000
12000
10000
*
TNF- [mg/mL]
*
8000
6000
4000
2000
0
*
*
C
G
DC
EOD
EOC
C
G
DC
EOD
C
EO
D
EO
G
C
D
C
EO
D
EO
G
D
C
C
C
Adiponectine [mg/mL]
As for TNF-, the groups of animals treated with the essential oil (EOD and EOC)
showed a decrease in the plasma concentration of this cytokine compared to that presented by its controls, Figure 5B. Interestingly, the group of diabetic animals treated
with glibenclamide (G), commercial hypoglycemic, showed a significant increase
in TNF- concentration compared to their control, the DC group and the animals
treated with the essential oil.
EOC
Figure 5. Concentration of (A) Adiponectin and (B) TNF-α, present in the serum of the different
groups of animals evaluated after 21 days of treatment. Groups: (C) control, (DC) Diabetic, (G)
Diabetic glibenclamide 10 mg/kg, (EOD) diabetic AE and (EOC) AE control. Values are presented as means ± SEM. * P <0.05.
419
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
Discussion
The essential oil of L. alba Mill N.E. Brown, carvone chemotype, used in the present
study, is non-toxic at the concentration used (500 μL/kg). There were no deaths, behavioral changes, or hepatotoxicity (did not occur with either single dose or repeated doses
of EO). Therefore, its LD50 is much higher than 500 μL/kg b.w. This is supported with
Olivero-Verbel et al. [17], who evaluated the toxicity of the essential oil of L. alba Mill
N.E. Brown, citral chemotype, administered intraperitoneally. The authors found that
the toxic effects of this oil were shown with doses equal to or greater than 1000 mg/
kg (b.w.).
About figure 1, it can be deduced that STZ does not alter the absorption of glucose
at the intestinal level, this is supported by the increase of glucose 30 minutes after the
glucose load supply to the animals. On the other hand, it should be emphasized that
the dose of this drug in the study does not completely destroy the Langerhans β cells
responsible for insulin production (the slope observed in figure 1 between minutes
30-120). Which brings the model used closer to what happens in T2DM.
An interesting effect shown by this EO is the regulatory effect of body weight (see figure 2). Asnaashari et al. [22]) report that the essential oil of Citrus aurantifolia, whose
main component is D-limonene (28.27%), also prevents body weight gain, due to a
decrease in appetite and energy. Therefore, Najafian [23] argues that body weight gain
can be reduced by administering essential plant extracts or oils because they contain
molecules that act as inhibitors of α-amylases. In fact, Najafian and Ebrahim-Habibi
[24], who worked with citral, a compound found in several essential oils like Backhousia citriodora, L. alba (citral chemotype), among others, found that it promotes
weight loss, decreases levels of glucose and has moderate activity in the inhibition of
α-amylases. This could explain the reduction in serum glucose levels as well as body
weight gain. In contrast with the results reported by Najafian, the present research
found a normal glucose absorption, then the α-amylase inhibitions is not the pathway
that explains the weight loss. The identification of the weight loss metabolic pathway
reason is beyond of the research scope.
Animals in the EOC group decreased glucose and triglyceride levels by 33 and 35%,
respectively, compared to the control group. It is noteworthy that in the animals that
were induced diabetes with STZ, there are no significant changes in glucose and triglyceride concentrations compared to their controls which could indicate that the oil
cannot reverse the metabolic effects caused by the STZ (see figure 4).
420
Effect of Lippia alba EO administration in Wistar rats
As for adipocytokines, it was found that EO caused a significant decrease in TNFalpha between the groups treated with EO (EOC and EOD) congruent with the antiinflammatory properties of EO. On the other hand, the results show that there are no
significant changes in the concentration of adiponectin in the different treated groups
(see figure 5A). The observed changes for this molecule could be since the groups treated
with the oil were the ones that gained the least weight (adiponectin increases have been
reported when there is weight loss [25-27] or could be due to genetic activation caused
by Oil. New experiments should be planned to solve this dilemma. Increases in adiponectin and decreased TNFα are related in the literature with decreased resistance to
insulin action [11, 27-29].
The increase in TNFα caused by the commercial hypoglycemic agent glibenclamide,
which, together with the body weight achieved by these animals, would indicate that
in subsequent studies this drug should not be used as an internal control (see figure 2
and figure 5 B).
Conclusions
In conclusion, the decrease in TNF- and body weight presented by the animals
treated with L. alba, carvone chemotype EO indicate that its components represent a
therapeutic alternative in the treatment of disease as obesity and T2DM complementary to hypocaloric diet and aerobic exercise.
Acknowledgments
The authors are especially grateful for the collaboration of the director of the research
group of Neurosciences -UIS, Ph.D. Carlos Conde, as well as the technician of the
UIS Bioterium, Mr. Jesús Rodríguez. We are also grateful for the collaboration of Estelia Carolina Méndez, professor at UIS School of Chemistry, and for the support of
the SINAT Research Group belonging to CINTROP ( Juan Sebastián Arias Flores,
Angélica María Martínez Delgado, Pedro José Iván Gómez Higuera, and Araceli Pinilla Plata).
Funding was provided by Vice-Rectory of Research and Extension (VIE) of Universidad Industrial de Santander with the grant number 1394 and the Young Researchers
2013 Program of Colciencias.
Disclosure statement
The authors declare no conflict of interest.
421
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
References
1.
G.S. Hotamisligil, Inflammation, metaflammation and immunometabolic disorders, Nature, 542(7640), 177-185 (2017).
2.
M.D. Lane, Q.Q. Tang, M.S. Jiang, Role of the CCAAT enhancer binding
proteins (C/EBPs) in adipocyte differentiation, Biochem. Biophys. Res. Commun., 266(3), 677-683 (1999).
3.
K.E. Wellen, G.S. Hotamisligil, Inflammation, stress, and diabetes, J. Clin. Invest.,
115(5), 1111-1119 (2005).
4.
T. Hennebelle, S. Sahpaz, H. Joseph, F. Bailleul, Ethnopharmacology of Lippia
alba, J. Ethnopharmacol., 116(2), 211-222 (2008).
5.
L.F. Ospina, R. Pinzón-Serrano, Plantas usadas como antidiabéticas en la medicina popular colombiana, Rev. Colomb. Cienc. Quím. Farm., 23, 81-94 (1995).
6.
M.E. Pascual, K. Slowing, E. Carretero, D. Sánchez-Mata, A. Villar, Lippia: traditional uses, chemistry and pharmacology: A review, J. Ethnopharmacol., 76(3),
201-214 (2001).
7.
V.Y. Hatano, A.S. Torricelli, A.C. Giassi, L.A. Coslope, M.B. Viana, Anxiolytic
effects of repeated treatment with an essential oil from Lippia alba and (R)-(-)carvone in the elevated T-maze, Braz. J. Med. Biol. Res., 45(3), 238-243 (2012).
8.
A.C. Mesa-Arango, J. Montiel-Ramos, B. Zapata, C. Durán, L. Betancur-Galvis,
E. Stashenko, Citral and carvone chemotypes from the essential oils of Colombian Lippia alba (Mill.) N.E. Brown: Composition, cytotoxicity and antifungal
activity, Mem. Inst. Oswaldo Cruz, 104, 878-884 (2009).
9.
E.E. Stashenko, B.E. Jaramillo, J.R. Martínez, Comparación de la composición
química y de la actividad antioxidante in vitro de los metabolitos secundarios
volátiles de plantas de la familia verbenaceae, Rev. Acad. Colomb. Cienc., 27(105),
579-598 (2003).
10.
T.G. Vale, F.J.A. Matos, T.C.M. De Lima, G.S.B. Viana, Behavioral effects of
essential oils from Lippia alba (Mill.) N.E. Brown chemotypes, J. Ethnopharmacol., 167, 127-133 (1999).
11.
E. Acosta-García, Obesidad, tejido adiposo y resistencia a la insulina, Acta Bioquím. Clín. Latinoam., 46(2), 183-194 (2012).
422
Effect of Lippia alba EO administration in Wistar rats
12.
K. Ohashi, R. Shibata, T. Murohara, N. Ouchi, Role of anti-inflammatory adipokines in obesity-related diseases, Trends Endocrinol. Metab., 25(7), 348-355
(2014).
13.
Directiva 2010/63/UE del Parlamento Europeo y del Consejo de 22 de septiembre de 2010 relativa a la protección de los animales utilizados para fines científicos, Diario Oficial de la Unión Europea, L 276, pp. 33-79. URL: https://www.
boe.es/doue/2010/276/L00033-00079.pdf
14.
OECD, Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure, OECD
Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris,
2008, pp. 1-27. URL: https://doi.org/10.1787/9789264071049-en.
15.
S. Hemalatha, A.K. Wahi, P.N. Singh, J.P.N. Chansouria, Hypoglycemic activity
of Withania coagulans Dunal in streptozotocin induced diabetic rats, J. Ethnopharmacol., 93, 261-264 (2004).
16.
S. Lenzen, The mechanisms of alloxan- and streptozotocin-induced diabetes,
Diabetologia, 51(2), 216-226 (2008).
17.
J. Olivero-Verbel, A. Guerrero-Castilla, E. Stashenko, Toxicity of the essential oil
of the cytral chemotype of Lippia alba (Mill.) N.E. Brown, Acta Toxicol. Argent.,
18(1), 21-27 (2010).
18.
K. Srinivasan, P. Ramarao, Animal models in type 2 diabetes research: An overview, Indian J. Med. Res., 125(3), 451-472 (2007).
19.
M.J. Reed, K.A. Scribner, In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery, Diabetes Obes. Metab., 1(2), 75-86 (1999).
20.
A. Junod, A.E. Lambert, W. Stauffacher, A.E. Renold, Diabetogenic action
of streptozotocin: relationship of dose to metabolic response, J. Clin. Invest.,
48(11), 2129-2139 (1969).
21.
M. García-Martín, A. Zurita-Molina, Transaminasas: valoración y significación
clínica, Protocolos diagnóstico-terapéuticos de gastroenterología, hepatología y
nutrición pediátrica, Asociación Española de Pediatría, Madrid, 2010, pp. 267275. URL: https://www.aeped.es/sites/default/files/documentos/transaminasas.pdf
22.
S. Asnaashari, A. Delazar, B. Habibi, R. Vasfi, L. Nahar, S. Hamedeyazdan et al.,
Essential oil from Citrus aurantifolia prevents ketotifen-induced weight-gain in
mice, Phyther. Res., 24(12), 1893-1897 (2010).
423
Maria Victoria Acevedo-Estupiñan, Elena Stashenko, Fernando Rodríguez-Sanabria
23.
M. Najafian, A review of alpha-amylase inhibitors on weight loss and glycemic
control in pathological state such as obesity and diabetes, Comp. Clin. Path.,
25(6), 1253-1264 (2014).
24.
M. Najafian, A. Ebrahim-Habibi, P. Yaghmaei, K. Parivar, B. Larijani, Citral as
a potential antihyperlipidemic medicine in diabetes: A study on streptozotocininduced diabetic rats, Iran. J. Diabetes Lipid Disord., 10(21), 1-8 (2011).
25.
M. Gil-Campos, R.R. Cañete, A. Gil, Adiponectin, the missing link in insulin
resistance and obesity, Clin. Nutr., 23(5), 963-974 (2004).
26.
M. Guerre-Millo, Adiponectin: An update, Diabetes Metab., 34(1), 12-18
(2008).
27.
E. Maury, S.M. Brichard, Adipokine dysregulation, adipose tissue inflammation
and metabolic syndrome, Mol. Cell. Endocrinol., 314(1), 1-16 (2010).
28.
I. Nieto-Vazquez, S. Fernández-Veledo, D.K. Krämer, R. Vila-Bedmar, L. Garcia-Guerra, M. Lorenzo, Insulin resistance associated to obesity: The link TNFalpha, Arch. Physiol. Biochem., 114(3), 183-194 (2008).
29.
S. Mirza, M. Hossain, C. Mathews, P. Martinez, P. Pino, J.L. Gay et al., Type
2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin
and low levels of leptin in a population of Mexican Americans: A cross-sectional
study, Cytokine, 57(1), 136-142 (2012).
How to cite this article
M.V. Acevedo-Estupiñan, E. Stashenko, F. Rodríguez-Sanabria, Effect of Lippia alba
essential oil administration on obesity and T2DM markers in Wistar rats, Rev. Colomb.
Cienc. Quím. Farm., 48(2), 411-424 (2019).
424